Introduction
The Nucleotide binding and Oligomerisation Domain (NOD) proteins NOD1 and NOD2 are the intracellular receptors for peptidoglycan, a major component of bacterial cell walls. The minimal sub-fragments of peptidoglycan recognised by NOD1 and NOD2, are muramyl-NAc-L-Ala-D-Glu-meso-diaminopimelic acid (MTri DAP ) and muramyl dipeptide (MDP), respectively, which bind to the C-terminal leucine rich repeat (LRR) domains of these proteins. NOD1 and NOD2 interact with a protein kinase, termed receptor-interacting protein 2 (RIP2, also called RICK, RIPK2
and CARDIAK), which is required for "downstream" signaling. NOD1 and NOD2 acting via RIP2, switch on the transcription factor NFκB and the mitogen-activated protein kinases (MAPKs) termed p38α MAPK, c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase 1 (ERK1) and ERK2 [1] [2] [3] , which stimulate production of the pro-inflammatory cytokines that mount innate immune responses to combat invading bacteria.
The NOD1/NOD2-RIP2 signaling pathway is thought to be used for host defence against intracellular bacteria that have evaded the Toll-like receptor (TLR)-mediated defence mechanisms in the plasma membrane, such TLR4 which responds to bacterial lipopolysaccharide (LPS). The NOD1/NOD2 signaling pathway may also provide a defence against gram-positive bacteria whose cell walls do not contain LPS [1] . The importance of NOD2 in protection against inflammatory bowel disease has been highlighted by the finding that particular mutations in NOD2 are associated with the susceptibility to Crohn's disease [1, [3] [4] [5] [6] [7] . Significantly, Peripheral Blood Mononuclear Cells (PBMC) from these patients do not produce the cytokines interleukin 1β (IL-1β), IL-10 or tumour necrosis factor α (TNFα) in response to either MDP or M-Tri DAP , demonstrating that NOD2 is also required for signaling by NOD1 in these cells [8] . However, NOD2 clearly plays additional roles in regulating also protected against LPS-induced septic shock and have impaired ability to defend against infection by Listeria monocytogenes [9] .
How the MDP-NOD2-RIP2 signaling module actually switches on "downstream" signaling is unclear because, surprisingly, when over-expressed in HEK 293 cells, a catalytically inactive ("kinase inactive", KI) mutant of RIP2 was reported to be as effective as wild type (WT) RIP2 in activating NFκB-dependent gene transcription and c-Jun N-terminal kinase (JNK) [10] or in triggering apoptosis [11] . Thus the protein kinase activity of RIP2 is thought not to be essential for the MDP-induced activation of these signaling pathways. These observations raised the question of how RIP2 switches on "downstream" signaling events and what function its associated kinase activity might have.
In this paper we demonstrate that the protein kinase activity of RIP2 plays at least two roles in the MDP-NOD2 signaling system. First, we find that KI-RIP2 is even more effective than WT-RIP2 in activating NFκB-dependent gene transcription, c-Jun N-terminal kinases 1 and 2 (JNK1/JNK2) and p38α mitogen-activated protein kinase (p38α MAPK), suggesting that RIP2 kinase activity functions to limit the strength of "downstream" signaling. Second, we find that RIP2 kinase activity is required to maintain RIP2 expression levels in transfected HEK 293 cells, which may explain our finding that pharmacological inhibition of the endogenous RIP2 kinase activity suppresses the MDP-induced activation of NFκB. We also find that, when over-expressed, RIP2 interacts with and activates TGFβ-activated kinase 1 (TAK1) and that MDP-NOD2 or RIP2 induced NFκB gene transcription does not occur when TAK1 is inhibited or in TAK1-deficient cells. Finally, we find that the MDP-induced signaling and production of IL-1β and TNFα in human PBMC is attenuated by pharmacological inhibition of p38α MAPK, MAPK kinase-1 (MKK1) or TAK1.
Taken together, our results suggest that the signaling pathways by which MDP-NOD2
and LPS-TLR4 induce the production of IL-1β and TNFα converge at the level of TAK1.
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Experimental
Materials
PD 184352 synthesised by an improved method [12] and BIRB 0796 synthesised from 4,4-dimethyl-3-exopentanenitrile [13] were provided by Natalia Shpiro and Rudolfo Marquez. SB 203580 was purchased from Promega, the Src family kinase inhibitors PP1 and PP2 from Calbiochem, the TAK1 inhibitor (5Z-7-oxo-zeaenol) from AnalytiCon Discovery GmbH, LPS and muramyl dipeptide free of LPS from Invivogen and the MEF2 nucleofection kit from Amaxa.
DNA constructs
DNA encoding human RIP2 (NP_003812) was amplified from IMAGE clone 4026156 (Geneservice) with oligonucleotides MP1155 and MP1160 using the GC Rich PCR System (Roche), cloned into a pCR2.1 vector. The construct was sequenced then ligated into the BamH1 /Not1 sites in the pCMV HA-1 vector. A vector in which Asp164 was changed to Ala (pCMV HA-RIP2[D164A]) was created using the Quickchange Mutagenesis kit (Stratagene) with oligonucleotides MP2345 and MP2346 and a vector in which Thr95 was changed to Met (pCMV HA-RIP2[T95M] was created using oligonucleotides MP2847 and MP2848. Mouse NOD2 (BC044774) was amplified from IMAGE clone 5324763 as described above with oligonucleotides MP1879 and MP1880 and cloned into the BamH1 site of pCMV HA-1.
The oligonucleotide sequences were:- 
MP1155 -GCGCGGCCGCCAACGGGGAGGCCATCTGCAGC
MP1160 -GCGGCCGCTTACATGCTTTTATTTTGAAGTAAATTTAAAGATG GTGATCTAGAAA
MP1879 -GCGGATCCATGTGCTCACAGGAAGAGTTCCAGGC
MP1880 -GCGGATCCTCACAACAAGAGTCTGGCGTCCCTG
MP2345 -CATGTTAAGATTGCAGCTTTTGGTTTATCAAAG
MP2346 -CTTTGATAAACCAAAAGCTGCAATCTTAACATG
MP2847 -TTTTTGGGAATAGTTATGGAATACATGCCAAAT
MP2848 -ATTTGGCATGTATTCCATAACTATTCCCAAAAA
DNA encoding a ConA basal promoter into which three copies of the NFκB DNA response element had been inserted (termed 3x κB luciferase reporter construct) and constructs encoding gag-pol and VSV-G for the production of Lentiviruses were provided by Ron Hay, College of Life Sciences University of Dundee [14] . The TAK1 short hairpin (shRNA) lentiviral plasmid was from Sigma and the pRL-TK vector driving Renilla luciferase from Promega.
Production of lentiviruses and infection
Lentiviruses carrying a TAK1 shRNA plasmid (TRCN0000001558, Sigma) were produced using a gag-pol construct and a VSV-G encoded plasmid by triple transfection as described [15] . To create stable cell lines 200 µl viral supernatant were used to infect HEK 293 cells on a 10 cm 2 dish. After 48 h, 3 µg puromycin was added
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DNA mixture added to a 0.4 cm electrode gap electroporation cuvette and shocked in a BioRad GenePulser II (300V, 950 µFD) at 21 o C. Cells were resuspended immediately in 1 ml of pre-warmed growth medium and aliquots (1.6 x 10 6 cells) added to 6 well plates and treated as described in Results.
For the measurement of NFκB-dependent luciferase gene expression, cells
were lysed in Passive Lysis Buffer (Promega) and luciferase activity measured using a Dual-Luciferase Reporter Assay System (Promega) according to the manufacturer's instructions. Firefly luciferase activity was normalised on the basis of Renilla luciferase activity.
Antibodies
Anti-TAK1, the antibody recognising TAB1 phosphorylated at Thr431 [18] and an antibody that recognises TAK1 phosphorylated at Thr187 (raised against the peptide IQTHMT*NNKGS, where T* is phospho-threonine) were raised in sheep. The antibody that recognises TAK1 phosphorylated at Thr187 was affinity purified on a phospho-peptide antigen-agarose column and used for immunoblotting in the presence of 10 µg/ml of the unphosphorylated peptide immunogen. Antibodies recognising the active phosphorylated forms of JNK, p38α MAPK and ERK1/ERK2
were from Cell Signaling Technologies, anti-TAK1 from Santa Cruz, anti-HA and anti-myc from Sigma Chemical Company and anti-human IL-1β from R&D Systems.
Immunoblotting
Cells were extracted in "standard lysis buffer" (50 mM Tris-HCl pH 7.5, 0.1 mM EGTA, 1 mM EDTA, 1% (w/w) Triton X-100, 1 mM Na 3 VO 4 , 50 mM NaF, 5 mM sodium pyrophosphate, 0.27 M sucrose, 0.1% mercaptoethanol, 'complete' proteinase inhibitor cocktail (Roche). After centrifugation for 15 min at 18,000 x g the supernatant (termed cell extract) was decanted and protein concentrations measured by the Bradford method. Moreover, SB 203580 did not affect the level of expression of the catalytically inactive mutant (Fig 2B) .
SB 203580 not only inhibits p38α MAPK and RIP2, but also two other protein kinases (CK1 and cyclin G-associated protein kinase (GAK)) [21] . It could therefore be argued that the effect of SB 203580 to reduce the level of expression of the RIP2 protein was caused not by the inhibition of RIP2 kinase activity, but by the inhibition of p38α MAPK, CK1 or GAK. In order to address this possibility we repeated the experiment using BIRB 0796, a much more potent inhibitor of p38α MAPK than SB 203580 [22, 23] , which does not inhibit RIP2 (Fig 2A) , CK1 or GAK (L. Cummings, to a hydrophobic pocket near the ATP-binding site [24, 25] . Since RIP2 possesses a threonine residue at the equivalent position, it seemed likely that the presence of this residue was critical for the sensitivity of RIP2 kinase activity to the drug. We In order to investigate whether the endogenous RIP2 kinase activity is required for MDP-induced signaling, we initially performed experiments in HEK 293 cells. Although these cells do not express NOD2 and therefore do not respond to MDP, sensitivity to MDP can be conferred by transfection with DNA encoding NOD2 [26] . When relatively large amounts of NOD2 DNA (10 ng per 10 cm 2 dish)
were transfected, NFκB-dependent reporter gene expression was activated but little further stimulation by MDP could be detected (Fig 3A) , presumably because NOD2 possesses some intrinsic ability to signal, even in the absence of MDP, which in overexpression experiments is sufficient to activate the pathway. However, when the amount of NOD2 DNA transfected was reduced to 1 ng, there was little activation of NFκB transcription in the absence of MDP, but MDP could now induce a 5-to 10-fold increase in NFκB-dependent gene transcription ( Fig 3A) .
We found that PP1 and PP2, which are potent inhibitors of Src family protein well authenticated physiological substrate of p38α MAPK [18] . Thus the effects of SB 203580 and PP2 are not mediated by the inhibition of p38α MAPK.
To investigate whether SB 203580 inhibits MDP signaling in a cell that normally expresses NOD2 and RIP2, we carried out further experiments in RAW 264.7 cells, a transformed mouse macrophage cell line. In these cells, MDP (presumably acting through the endogenous NOD2 and RIP2) stimulated NFκB-dependent reporter gene transcription, which was suppressed by SB 203580, but not by BIRB 0796 (Fig 3F) . In contrast, LPS-stimulated NFκB-dependent gene transcription was unaffected by either SB 203580 or BIRB 0796 (Fig 3F) .
TAK1 is required for signaling downstream of NOD2 and RIP2.
The protein kinase TAK1 is known to play an essential role in mediating the LPS-induced activation of NFκB, JNK and p38α MAPK and the production of proinflammatory cytokines in vivo [16, [27] [28] [29] , raising the question of whether TAK1
was also essential for MDP-NOD2/RIP2 signaling to NFκB and MAP kinases.
Consistent with the potential involvement of TAK1, this protein kinase has been reported to interact with NOD2 in co-transfection experiments [30] . These investigators also reported that the MDP-induced activation of NFκB-dependent gene expression was suppressed by the over-expression of a catalytically inactive "dominant negative" form of TAK1. Moreover, they also observed that the overexpression of NOD2 inhibited TAK1-induced NFκB activation in RIP2-deficient fibroblasts. Based on these experiments, they concluded that the NOD2 signaling pathway antagonises TAK1-mediated signaling and vice versa [30] .
We have confirmed the previous report that NOD2 interacts with TAK1 ( Fig   4A) and, in addition, found that RIP2 interacts with TAK1 in co-transfection experiments ( Fig 4B) . This interaction between RIP2 and TAK1 is likely to be direct and not indirect via NOD2, because HEK 293 cells do not express NOD2.
Importantly, we also found that the endogenous TAK1 (measured by the phosphorylation of Thr187 [31] ) and JNK were activated by transfection with DNA encoding either WT-RIP2 or KI-RIP (Fig 4C) and that a catalytically inactive TAK1 mutant suppressed the RIP2-induced phosphorylation (activation) of endogenous JNK and p38α MAPK (Fig 4D) . Therefore, in contrast to the conclusions reached earlier [30] , our experiments suggested that TAK1 was not a negative regulator of NOD2-RIP2 signaling, but instead might be essential for signaling through this pathway. In order to investigate whether this was the case, we first reduced the level of expression of TAK1 by 80-90% in HEK 293 cells by introducing a vector expressing a short hairpin RNA (Fig 5A) . This suppressed by 65-70% the activation of NFκB induced by either the over-expression NOD2-or RIP2 (Fig 5B) or by MDP in the presence of low levels of transfected NOD2 (Fig 5C) . In parallel experiments RIP2-induced JNK activation was similarly reduced by shRNA knockdown of TAK1 (results not shown).
In order to confirm these results by an independent method, we studied the effect of 5Z-7-oxo-zeaenol, which has been reported to be a potent and relatively specific inhibitor of TAK1 [32] . These experiments showed that this compound suppressed MDP-stimulated NFκB gene transcription by about 70% when included in the cell culture medium at 1 µM (Fig 5D) . We found that this concentration was needed to completely suppress IL-1-stimulated activated of JNK, p38α MAPK and ERK1/ERK2 in IL-1R cells (data not shown).
We then studied the effects of NOD2 and RIP2 on NFκB gene transcription in immortalised embryonic fibroblasts from wild type mice and TAK1-/-mice. These experiments showed that transfection with DNA expressing either NOD2 or RIP2 stimulated NFκB-dependent gene transcription in the wild type cells, but no stimulation occurred in the TAK1-deficient cells (Fig 5E) .
MDP-induced production of interleukin-1β in peripheral blood mononuclear cells (PBMC) is prevented by specific inhibition of TAK1, p38α MAPK or
MKK1/MKK2.
The experiments described above indicated that TAK1 represents an important point of convergence of the LPS-TLR4 and MDP-NOD2 signaling pathways, suggesting that many subsequent downstream events might be common to both pathways. We therefore investigated the signaling pathways required for the MDP-induced production of the pro-inflammatory cytokines IL-1β and TNFα in human PBMC, a more physiological system in which the cells are known to respond particularly well to this agonist [8] .
To examine whether TAK1 activity is required for signaling by MDP in human PBMC, we studied the effect on the TAK1 inhibitor 5Z-7-oxo-zeaenol. When added to the culture medium at 1 µM, this compound prevented both the MDPstimulated and LPS-stimulated secretion of IL-1β (Fig 6A) and TNFα (Fig 6B) and the MDP-or LPS-induced production of pro-IL-1β (Fig 6C) in human PBMC.
Two protein kinases activated downstream of TAK1 and required for the LPSinduced production of a number of pro-inflammatory cytokines are p38α MAPK [20] and tumour progression locus 2 (Tpl2, also called COT) [33] . The p38α MAPK activates MAPK-activated protein kinase 2 (MAPKAP-K2), which is required for the LPS-induced production of several pro-inflammatory cytokines [34] , while Tpl2
activates the MAP kinase kinases MKK1 and MKK2 and hence ERK1/ERK2 [33] .
We found that, as for LPS, MDP induced the activation of ERK1/ERK2 within 60 min in human PBMC (Fig 7A) and that this was prevented by PD 184352 (Fig 7B) , a potent and specific inhibitor of the MKK1/MKK2 [35, 36] . PP2, a potent inhibitor of RIP2 (Fig 3B) , suppressed the MDP-induced, but not LPS-induced activation of ERK1/ERK2, indicating that RIP2 kinase activity is required for MDP signaling to ERK1/ERK2 in human PBMC (Fig 7C) .
Like LPS, MDP stimulated the secretion IL-1β and TNFα in human PBMC, and this was suppressed by PD 184352 or the p38α MAPK inhibitor BIRB 0796 ( Figs 8A and 8B ). The BIRB 0796 was used at a concentration of 0.1 µM, at which it inhibits p38α/β MAPKs specifically, but does not inhibit RIP2 (Fig 2A) or many other protein kinases tested [22] . PD 184352 (Fig 8C) or BIRB 0796 (Fig 8D) also prevented the MDP-or LPS-induced expression of pro-IL-1β, demonstrating that these drugs exert their effects by blocking pro-IL-1β expression, rather than just IL-1β secretion.
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It should be mentioned that PBMC from different human donors showed large quantitative differences in the amount of IL-1β or TNFα produced in response to MDP or LPS, although sensitivity to BIRB 0796 and PD 184352 was unaltered.
However, in two donors, MDP-stimulated production of IL-1β in PBMC was only inhibited 50% and 70%, respectively, by BIRB 0796 and 90% and 70%, respectively, by PD 184352, whereas in other donors these inhibitors caused almost complete suppression (Christine Lang, unpublished experiments).
Discussion
At the time RIP2 was first identified it was noticed that, when over-expressed in HEK 293 cells, a catalytically inactive (KI, "kinase inactive") mutant was as effective as the wild type protein in activating JNK or NFκB [10] or inducing the apoptosis of MCF7 breast sarcoma cells [11] . These observations raised the question of what role the protein kinase activity of RIP2 might have. Here, we demonstrate that KI-RIP2 is much more effective than WT-RIP2 in activating JNK and NFκB in transfected HEK 293 cells (Figs 1 and 2) , indicating that the protein kinase activity functions to limit the strength of signaling under these conditions. The molecular events that underlie this action are unknown, but since HEK 293 cells do not express NOD2, it cannot be explained by RIP2 exerting a negative feedback control on NOD2. Thus mechanisms involving a RIP2 kinase-catalysed enhancement of the interaction of NOD2 with an inhibitory protein, such as Erbin [37, 38] , appear to be excluded. RIP2 is known to phosphorylate itself at multiple sites [39] , raising the possibility that the autophosphorylated protein kinase is less effective than the unphosphorylated form of the enzyme in activating TAK1 and/or other proteins that drive "downstream" signaling events.
We have also shown that the protein kinase activity of RIP2 is required to maintain its level of expression in transfected HEK 293 cells. Thus KI-RIP2 was expressed at much lower levels than WT-RIP2, while pharmacological inhibition with Fig 2C) . Interestingly, the SB 203580-induced decrease in expression of RIP2 is quite fast, being complete within 30-60 min, but preliminary experiments indicate that this cannot be prevented by either the proteasome inhibitor MG 132, or a specific inhibitor of caspase 1 (M.
Windheim and P. Cohen, unpublished results), a proteinase that interacts with and is activated by NOD2 [40] . Thus the mechanism that leads to the disappearance of activated RIP2 has still to be clarified.
Importantly, we found that the MDP-stimulated activation of NFκB gene transcription in NOD2-transfected HEK 293 cells or in untransfected RAW 264.7 cells was prevented by SB 203580 or PP2, but not by the much more potent p38α MAPK inhibitor BIRB 0796, which does not inhibit RIP2 (Fig 3) . Our working hypothesis is that MDP induces the active conformation of RIP2, which then phosphorylates itself or another regulatory protein, leading to stabilisation of the activated enzyme. Pharmacological inhibition of RIP2 kinase prevents this stabilisation and the MDP-induced downstream signaling does not occur because the level of expression of RIP2 falls below the threshold needed for signaling to occur.
We assume that KI-RIP2 is able to trigger MDP-dependent NFκB gene transcription in transfected cells, because it is expressed at supra-physiological levels under these conditions, well in excess of those needed to support signaling. To our knowledge, the present study represents the first evidence that the protein kinase activity of RIP2 is required for signaling "downstream" of MDP-NOD2. Interestingly, knock-in mice that express the catalytically inactive RIP2[K47A] mutant instead of WT-RIP2 also exhibit decreased expression of the mutant enzyme [41] . It would clearly be of considerable interest to know whether MDP is capable of stimulating NFκB-dependent gene transcription and pro-inflammatory cytokine production in these animals, but this was not investigated in the published study [41] .
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In contrast to the inhibition of MDP-stimulated NFκB gene transcription by SB 203580 and PP2, LPS-stimulated and IL-1 stimulated NFκB reporter gene transcription in RAW 264.7 ( Fig 3F) and IL-1R cells (Fig 3D) , respectively, were unaffected by SB 203580 and PP2. Moreover, PP2 suppressed MDP-induced, but not LPS-induced activation of ERK1/ERK2 in human PBMC (Fig 7C) Thus, although LPS stimulates RIP2 kinase activity [39, 41] , RIP2 kinase activity is not rate limiting for LPS-induced activation of NFκB and ERK1/ERK2. Other investigators also reported that RIP2 was not required for signalling through LPS-TLR4 or other TLRs, while this paper was undergoing revision [42] .
TAK1 is thought to play an essential role in the LPS-induced activation of signaling pathways and the production of pro-inflammatory cytokines [16, [27] [28] [29] and, in this paper, we demonstrate that TAK1 is also required for MDP-NOD2/RIP2
signaling (Figs 4, 5) and proinflammatory cytokine production (Fig 6) . These results imply that TAK1 represents one of the key points at which the LPS-TLR4 and MDP-NOD2 signaling pathways converge (Fig 9) , explaining why "downstream" events, such as the activation of NFκB, JNK, p38α MAPK and ERK1/ERK2, and the production of IL-1β and TNFα are common to both pathways (Figs 4-8 ). Consistent with a key role for TAK1, it has been reported that the over-expression of NOD2 or RIP2 activates IKKβ by inducing the phosphorylation of Ser177 and Ser 181 [43] , the sites phosphorylated by TAK1. Moreover, as for LPS, the activation of p38α MAPK and ERK1/ERK2 are both required for the MDP-induced production of Pro-IL-1β, secreted IL-1β or secreted TNFα in human PBMC (Fig 8) , which express endogenous levels of NOD2 and RIP2.
RIP2 is also known to be required for the signalling by M-Tri DAP -NOD1 (see Introduction). During the revision stage of this paper, other investigators reported that dominant negative TAK1 and siRNA knockdown of TAK1 reduced M-Tri DAP -NOD1-induced activation of JNK and IL-8 secretion [44] . This study indicates that TAK1
lies downstream of RIP2 in the NOD1 as well as the NOD2 signaling pathway.
A major outstanding question concerns the mechanism by which RIP2 triggers the activation of TAK1 and other "downstream" signaling events. The activation of TAK1 and IKKβ by TNFα, IL-1β or LPS is thought to be initiated by the formation of Lys63-linked polyubiquitin (K63-pUb) chains that become linked covalently to the protein kinases RIP [45, 46] and the E3 ligase TRAF6 [47] . These K63-pUb scaffolds interact with the NEMO regulatory subunit of the IKK complex and the TAB2/TAB3 regulatory subunits of the TAK1 complex, which may co-localise TAK1
and IKKβ and so facilitate the TAK1-catalysed phosphorylation and activation of IKKβ. The catalytic domain of RIP is most similar to RIP2, and like RIP2, the catalytic activity of RIP does not appear to be required for signalling by TNFα [48] , raising the question of whether RIP2 might also trigger downstream signaling by a mechanism that requires the Lys63-linked polyubiquitination of one or more proteins.
Indeed, it has been reported that NEMO undergoes Lys63-linked polyubiquitination when co-transfected with either NOD2 or RIP2 in HEK 293 cells [43] . Moreover, these effects were suppressed by co-transfection with vectors expressing the Lys63-specific deubiquitinating enzyme CYLD [43] . These observations have provided the first indication that Lys63-linked polyubiquitination of NEMO may be critical for the NOD2/RIP2-induced activation of IKKβ, which can lead to the activation of ERK1/ERK2 [49, 50] , as well as the activation of NFκB. However, as the NEMO-IKKβ complex does not participate in the activation of p38α MAPK or JNK (Fig 8) ,
it seems likely that additional devices are needed to mediate the NOD2/RIP2-induced activation of these MAPKs. 
